Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Blissaff Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Blissaff: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
BMB-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
BMB-101: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
ADR-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
ADR-002: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Navocaftor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Navocaftor: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
L2-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
L2-01: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
PF-05190457 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
PF-05190457: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
LT-4007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
LT-4007: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
AI-09 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
AI-09: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
CNTX-6016 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
CNTX-6016: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Tuvatexib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Tuvatexib: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Funapide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Funapide: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
KQB-198 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
KQB-198: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.